Related Experiment Videos
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer
1Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
Lung Cancer (Amsterdam, Netherlands)
|June 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Retrospective study evaluating dental side effects of radiotherapy in patients treated for head and neck cancer.
Journal of stomatology, oral and maxillofacial surgery·2024
Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict.
Journal of cancer policy·2022
Risk factors for imminent fractures: a substudy of the FRISBEE cohort.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios.
Lung cancer (Amsterdam, Netherlands)·2026
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Lung cancer (Amsterdam, Netherlands)·2026
The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer.
Lung cancer (Amsterdam, Netherlands)·2026
Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study.
Lung cancer (Amsterdam, Netherlands)·2026
Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.
Lung cancer (Amsterdam, Netherlands)·2026
Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.
Drug design, development and therapy·2026
PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.
Molecular therapy. Nucleic acids·2026
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.
Molecular therapy. Nucleic acids·2026